In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization
- PMID: 29800428
- DOI: 10.7326/ACPJC-2018-168-10-052
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization
Comment on
-
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13. Circulation. 2018. PMID: 28904068 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical